IP Library › Granted Patent US 12,493,047
Granted Patent B2
US 12,493,047 · App. 17/141,690 · Granted Dec 9, 2025

Cleaved high molecule weight kininogen (HMWK) antibodies and methods of using

Inventors: Daniel J. Sexton (Melrose, MA); Ryan Faucette (Melrose, MA); Janja Cosic (Arlington, MA)
Assignee: Takeda Pharmaceutical Company Limited
G01N33/6893C07K16/36G01N33/54306G01N33/86G01N2333/745G01N2800/50
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,493,047
App. No.
17/141,690
Granted
Dec 9, 2025
Kind
B2
Abstract

The present disclosure provides immunoassay methods of detecting a cleaved high molecular weight kininogen (HMWK) with high sensitivity and specificity and isolated antibodies that specifically bind cleaved HMWK.

Claims (5)

1 . An isolated antibody, which specifically binds a cleaved high molecular weight kininogen (HMWK),

wherein the antibody comprises a heavy chain complementarity determining region (CDR) 1 sequence FSFYVMV (SEQ ID NO: 84), a heavy chain CDR2 sequence GISPSGGNTAYADSVK (SEQ ID NO: 85), and a heavy chain CDR3 sequence KLFYYDDTKGYFDF (SEQ ID NO: 86) and a light chain CDR1 sequence SGSSSNIGSNYVY (SEQ ID NO: 87), a light chain CDR2 sequence RNNQRPS (SEQ ID NO: 88), and a light chain CDR3 sequence AWDDSLNGRV (SEQ ID NO: 89).

2 . The isolated antibody of claim 1 , wherein the antibody comprises a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO: 4 and a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO: 5.

3 . A kit for detecting a cleaved high molecular weight kininogen (HMWK), the kit comprising a first agent that specifically binds a cleaved HMWK; wherein the first agent is the isolated antibody of claim 1 .

4 . The kit of claim 3 , wherein the kit further comprises a second agent that binds HMWK, a support member, or both.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 17, 2025
From: DYAX CORP.
To: TAKEDA PHARMACEUTICAL COMPANY LIMITED
Reel/Frame 069909/0120 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 9, 2021
From: SEXTON, DANIEL J.; FAUCETTE, RYAN; COSIC, JANJA
To: DYAX CORP.
Reel/Frame 058057/0750 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 30, 2021
From: DYAX CORP.
To: TAKEDA PHARMACEUTICAL COMPANY LIMITED
Reel/Frame 055772/0327 →
Continuity (4)
Division 15769237
Provisional Application 62335311 · May 12, 2016
Provisional Application 62243505 · Oct 19, 2015
Related Publication 20210270842A1 · Sep 2, 2021
References Cited (208)
US 4882272A · Scott et al. · 1989 [cited by applicant]
US 4908431A · Colman et al. · 1990 [cited by applicant]
US 4985354A · Toyomaki et al. · 1991 [cited by applicant]
US 5025796A · Hargreaves et al. · 1991 [cited by applicant]
US 5047323A · Colman et al. · 1991 [cited by applicant]
US 5472945A · Schmaier et al. · 1995 [cited by applicant]
US 6242210B1 · Bjoerck et al. · 2001 [cited by applicant]
US 6913900B2 · Kaplan et al. · 2005 [cited by applicant]
US 8637454B2 · Sternlicht · 2014 [cited by applicant]
US 10101344B2 · Sexton et al. · 2018 [cited by applicant]
US 10648990B2 · Sexton et al. · 2020 [cited by applicant]
US 10914747B2 · Sexton · 2021 [cited by examiner]
US 11156612B2 · Sexton et al. · 2021 [cited by applicant]
US 11372002B2 · Sexton et al. · 2022 [cited by applicant]
US 12061206B2 · Sexton et al. · 2024 [cited by applicant]
US 20030049713A1 · Kaplan et al. · 2003 [cited by applicant]
US 20050223416A1 · Nuijens et al. · 2005 [cited by applicant]
US 20060069020A1 · Blair et al. · 2006 [cited by applicant]
US 20060115471A1 · Coleman et al. · 2006 [cited by applicant]
US 20070192882A1 · Dewald · 2007 [cited by applicant]
US 20080038276A1 · Sinha et al. · 2008 [cited by applicant]
US 20080213251A1 · Sexton et al. · 2008 [cited by applicant]
US 20080255025A1 · Ladner · 2008 [cited by applicant]
US 20080299549A1 · Sorge et al. · 2008 [cited by applicant]
US 20090075887A1 · McPherson · 2009 [cited by applicant]
US 20110154517A1 · Dewald · 2011 [cited by applicant]
US 20110200611A1 · Sexton · 2011 [cited by applicant]
US 20110212104A1 · Beaumont et al. · 2011 [cited by applicant]
US 20110318359A1 · Feener et al. · 2011 [cited by applicant]
US 20120201756A1 · Sexton · 2012 [cited by applicant]
US 20130156753A1 · Jin · 2013 [cited by applicant]
US 20140128436A1 · Sinha et al. · 2014 [cited by applicant]
US 20150362493A1 · Sexton et al. · 2015 [cited by applicant]
US 20160252527A1 · Sexton et al. · 2016 [cited by applicant]
US 20160252533A1 · Sexton et al. · 2016 [cited by applicant]
US 20180306807A1 · Sexton et al. · 2018 [cited by applicant]
US 20190120862A1 · Sexton et al. · 2019 [cited by applicant]
US 20200371120A1 · Sexton et al. · 2020 [cited by applicant]
US 20220170936A1 · Sexton et al. · 2022 [cited by applicant]
US 20220291232A1 · Sexton et al. · 2022 [cited by applicant]
US 20230072523A1 · Glozman · 2023 [cited by applicant]
US 20230408528A1 · Wu et al. · 2023 [cited by applicant]
CN 102405228A · 2012 [cited by applicant]
CN 102762203A2 · 2012 [cited by applicant]
EP 0210029A2 · 1987 [cited by applicant]
JP S63185398A · 1988 [cited by applicant]
JP H1084995A · 1998 [cited by applicant]
JP 2001503861A · 1998 [cited by applicant]
JP 2001124779A · 2001 [cited by applicant]
JP 2002221519A · 2002 [cited by applicant]
JP 2003159053A · 2003 [cited by applicant]
JP 2009521926A · 2009 [cited by applicant]
JP 2009545611A · 2009 [cited by applicant]
JP 2011051259A · 2011 [cited by applicant]
JP 2013516389A · 2013 [cited by applicant]
JP 2014506319A · 2014 [cited by applicant]
JP 2016505159A · 2016 [cited by applicant]
JP 2016511823A · 2016 [cited by applicant]
JP 2016536012A · 2016 [cited by applicant]
JP 2017500584A · 2017 [cited by applicant]
JP 2017503820A · 2017 [cited by applicant]
JP 2018117626A · 2018 [cited by applicant]
KR 1020100120788A · 2010 [cited by applicant]
KR 1020110057086A · 2011 [cited by applicant]
WO WO2004005934A2 · 2004 [cited by applicant]
WO WO2006101387A2 · 2006 [cited by applicant]
WO WO2007079096A2 · 2007 [cited by applicant]
WO WO2008064336A2 · 2008 [cited by applicant]
WO WO2009051259A1 · 2009 [cited by applicant]
WO WO2011075684A1 · 2011 [cited by applicant]
WO WO2012094587A1 · 2012 [cited by applicant]
WO WO2012170945A2 · 2012 [cited by applicant]
WO WO2012170947A2 · 2012 [cited by applicant]
WO WO2013079868A1 · 2013 [cited by applicant]
WO WO2014113712A1 · 2014 [cited by applicant]
WO WO2015061182A1 · 2015 [cited by applicant]
WO WO2015061183A1 · 2015 [cited by applicant]
WO WO2021094587A1 · 2021 [cited by applicant]
[No Author Listed], Image Studio Software Compatible with Mac® Systems Now Available from LI-COR!. BioB Blog. May 8, 2012:1-3. [cited by applicant]
[No Author Listed], Mouse High Molecular Weight Kininogen (HMWK) ELISA Kit (Cat. No. BMS089195). MyBiosource Datasheet. Jan. 2, 1984. Retrieved from <https://www.mybiosource.com/prods/ELIS-A-Kit/Mouse/High-Molecular-Wei… [cited by applicant]
Berrettini et al., Detection of in vitro and in vivo cleavage of high molecular weight kininogen in human plasma by immunoblotting with monoclonal antibodies. Blood. Aug. 1986;68(2):455-62. [cited by applicant]
Blais et al., The kallikrein-kininogen-kinin system: lessons from the quantification of endogenous kinins. Peptides. Dec. 2000;21(12):1903-40. Review. [cited by applicant]
Bühler et al., Improved detection of proteolytically cleaved high molecular weight kininogen by immunoblotting using an antiserum against its reduced 47 kDa light chain. Blood Coagul Fibrinolysis. May 1995;6(3):223-32. [cited by applicant]
Chaudhuri et al., Glucocorticoids and rheumatoid arthritis—a reappraisal. I. J. Rheumatol. Mar. 1, 2008;3(1):21-8. [cited by applicant]
Chyung et al., A phase 1 study investigating DX-2930 in healthy subjects. Ann Allergy Asthma Immunol. Oct. 2014;113(4):460-6.e2. doi: 10.1016/j.anai.2014.05.028. Epub Jun. 26, 2014. [cited by applicant]
Colman et al., Studies on the prekallikrein (kallikreinogen)—kallikrein enzyme system of human plasma. I. Isolation and purification of plasma kallikreins. J Clin Invest. Jan. 1969;48(1):11-22. [cited by applicant]
Cugno et al., Activation of factor XII and cleavage of high molecular weight kininogen during acute attacks in hereditary and acquired C1-inhibitor deficiencies. Immunopharmacology. Jun. 1996;33(1-3):361-4. [cited by applicant]
Cugno et al., Activation of the coagulation cascade in C1-inhibitor deficiencies. Blood. May 1, 1997;89(9):3213-8. [cited by applicant]
Cugno et al., Activation of the contact system and fibrinolysis in autoimmune acquired angioedema: A rationale for prophylactic use of tranexamic acid. J Allergy Clin Immunol. 1994;93(5):870-876. [cited by applicant]
Cugno et al., C1-inhibitor deficiency and angioedema: molecular mechanisms and clinical progress. Trends Mol Med. Feb. 2009;15(2):69-78. doi: 10.1016/j.molmed.2008.12.001. Epub Jan. 21, 2009. [cited by applicant]
Defendi et al., Enzymatic assays for the diagnosis of bradykinin-dependent angioedema. PLoS One. Aug. 5, 2013;8(8):e70140. doi:10.1371/journal.pone.0070140. Print 2013. Erratum in: PLoS One. 2014;9(6):e100345. [cited by applicant]
Devani et al., Kallikrein-kinin system activation in Crohn's disease: differences in intestinal and systemic markers. Am J Gastroenterol. Aug. 2002;97(8):2026-32. [cited by applicant]
Dobó et al., Cleavage of kininogen and subsequent bradykinin release by the complement component: mannose-binding lectin-associated serine protease (MASP)-1. PLoS One. 2011;6(5):e20036. doi: 10.1371/journal.pone.0020036… [cited by applicant]
Faucette et al., A Biomarker Assay For the Detection of Contact System Activation. Blood. 2013;122:2347. Available online at http://www.bloodjournal.org/conten/122/21/2347. Last accessed on Mar. 30, 2018. Abstract only. [cited by applicant]
Gallimore et al., Plasma levels of factor XII, prekallikrein and high molecular weight kininogen in normal blood donors and patients having suffered venous thrombosis. Thromb Res. 2004; 114(2):91-6. [cited by applicant]
Huang, Alzheimer Disease. Merck Manual, Professional Version. Dec. 2019:1-7. [cited by applicant]
Ishiguro et al., Mapping of functional domains of human high molecular weight and low molecular weight kininogens using murine monoclonal antibodies. Biochemistry. Nov. 3, 1987;26(22):7021-9. [cited by applicant]
Isordia-Salas et al., The mutation Ser511Asn leads to N-glycosylation and increases the cleavage of high molecular weight kininogen in rats genetically susceptible to inflammation. Blood. Oct. 15, 2003;102(8):2835-42. E… [cited by applicant]
Isordia-Salas et al., The role of plasma high molecular weight kininogen in experimental intestinal and systemic inflammation. Arch Med Res. Jan.-Feb. 2005;36(1):87-95. [cited by applicant]
Joseph et al., Studies of the mechanisms of bradykinin generation in hereditary angioedema plasma. Ann Allergy Asthma Immunol. Sep. 2008;101(3):279-86. doi: 10.1016/S1081-1206(10)60493-0. [cited by applicant]
Katori et al., Evidence for the involvement of a plasma kallikrein-kinin system in the immediate hypotension produced by endotoxin in anaesthetized rats. Br J Pharmacol. Dec. 1989;98(4):1383-91. [cited by applicant]
Kenniston et al., Inhibition of plasma kallikrein by a highly specific active site blocking antibody. J Biol Chem. Aug. 22, 2014;289(34):23596-608. doi: 10.1074/jbc.M114.569061. Epub Jun. 26, 2014. [cited by applicant]
Kerbiriou-Nabias et al., Radioimmunoassays of human high and low molecular weight kininogens in plasmas and platelets. Br J Haematol. Feb. 1984;56(2):273-86. [cited by applicant]
Khan et al., High-molecular-weight kininogen fragments stimulate the secretion of cytokines and chemokines through uPAR, Mac-1, and gC1qR in monocytes. Arterioscler Thromb Vasc Biol. Oct. 2006;26(10):2260-6. Epub Aug. 1… [cited by applicant]
Kontzias, Rheumatoid Arthritis (RA). Merck Manual, Professional Version. Dec. 2018:1-19. [cited by applicant]
Ladner et al., Discovery Of Ecallantide: A Potent And Selective Inhibitor Of Plasma Kallikrein. J Allergy and Clinical Immuno. Jan. 1, 2007;119(1):S312. [cited by applicant]
Maggio, Sepsis and Septic Shock. Merck Manual, Professional Version. Jan. 2020:1-8. [cited by applicant]
Mehta, Diabetic Retinopathy. Merck Manual, Professional Version. Jun. 2019:1-5. [cited by applicant]
Merlo et al., Elevated levels of plasma prekallikrein, high molecular weight kininogen and factor XI in coronary heart disease. Atherosclerosis. Apr. 2002;161(2):261-7. [cited by applicant]
Mutch et al., Immobilized transition metal ions stimulate contact activation and drive factor XII-mediated coagulation. J Thromb Haemost. Oct. 2012;10(10):2108-15. doi: 10.1111/j.1538-7836.2012.04890.x. [cited by applicant]
Nguyen et al., The Simple Western™: a gel-free, blot-free, hands-free Western blotting reinvention. Nature Methods. Oct. 28, 2011;8:5-6. [cited by applicant]
Nielsen et al., Hereditary angio-oedema: new clinical observations and autoimmune screening, complement and kallikrein-kinin analyses. J Intern Med. Feb. 1996;239(2):119-30. [cited by applicant]
Page et al., An autoantibody to human plasma prekallikrein blocks activation of the contact system. Br J Haematol. May 1994;87(1):81-6. [cited by applicant]
Phipps et al., Plasma kallikrein mediates angiotensin II type 1 receptor-stimulated retinal vascular permeability. Hypertension. Feb. 2009;53(2):175-81. Epub Jan. 5, 2009. [cited by applicant]
Raymond et al., Quantification of des-Arg9-bradykinin using a chemiluminescence enzyme immunoassay: application to its kinetic profile during plasma activation. J Immunol Methods. Mar. 27, 1995;180(2):247-57. [cited by applicant]
Reddigari et al., Cleavage of human high-molecular weight kininogen by purified kallikreins and upon contact activation of plasma. Blood. May 1988;71(5):1334-40. [cited by applicant]
Reddigari et al., Monoclonal antibody to human high-molecular-weight kininogen recognizes its prekallikrein binding site and inhibits its coagulant activity. Blood. Aug. 1, 1989;74(2):695-702. [cited by applicant]
Reddigari et al., Quantification of human high molecular weight kininogen by immunoblotting with a monoclonal anti-light chain antibody. J Immunol Methods. Apr. 21, 1989;119(1):19-25. [cited by applicant]
Schmaier et al., Determination of the bifunctional properties of high molecular weight kininogen by studies with monoclonal antibodies directed to each of its chains. J Biol Chem. Jan. 25, 1987;262(3):1405-11. [cited by applicant]
Schousboe et al., High molecular weight kininogen binds to laminin—characterization and kinetic analysis. FEBS J. Sep. 2009;276(18):5228-38. doi: 10.1111/j.1742-4658.2009.07218.x. Epub Aug. 19, 2009. [cited by applicant]
Scott et al., A new assay for high molecular weight kininogen in human plasma using a chromogenic substrate. Thromb Res. Dec. 15, 1987;48(6):685-700. [cited by applicant]
Scott et al., Sensitive antigenic determinations of high molecular weight kininogen performed by covalent coupling of capture antibody. J Lab Clin Med. Jan. 1992;119(1):77-86. Abstract only. [cited by applicant]
Sexton et al., Discovery and Characterization of a Fully Human Monoclonal Antibody Inhibitor of Plasma Kallikrein for the Treatment of Plasma Kallikrein-Mediated Edema. J. Allergy Clin. Immunol. Feb. 2013;131(2):AB32. [cited by applicant]
Sexton et al., Inhibition of the plasma kallikrein-kinin system activation by DX-2930, a fully human monoclonal antibody inhibitor of plasma kallikrein. Journal of Angioedema. May 2013;1(1): 45. [cited by applicant]
Syvänen et al., A radioimmunoassay for the detection of molecular forms of human plasma kininogen. FEBS Lett. Jul. 6, 1981;129(2):241-5. [cited by applicant]
Torzewski et al., Animal Models of c-Reactive Protein. Hindawi Publishing Corpl, Mediators of Inflammation. 2014:1-7. [cited by applicant]
Uchida et al., Differential assay method for high molecular weight and low molecular weight kininogens. Thromb Res. 1979;15(1-2):127-34. [cited by applicant]
Van Der Vekens et al., Human and equine cardiovascular endocrinology: beware to compare. Cardiovascular Endocrinology. 2013;2(4):67-76. [cited by applicant]
Veloso et al., A monoclonal anti-human plasma prekallikrein antibody that inhibits activation of prekallikrein by factor XIIa on a surface. Blood. Oct. 1987;70(4):1053-62. [cited by applicant]
Williams et al., DX-88 and HAE: a developmental perspective. Transfus Apher Sci. Dec. 2003;29(3):255-8. [cited by applicant]
Zhang et al., Two-chain high molecular weight kininogen induces endothelial cell apoptosis and inhibits angiogenesis: partial activity within domain 5. FASEB J. Dec. 2000; 14(15):2589-600. [cited by applicant]
Zuraw et al., New promise and hope for treating hereditary angioedema. Expert Opin Investig Drugs. May 2008;17(5):697-706. doi: 10.1517/13543784.17.5.697. [cited by applicant]
EP 14855002.3, Feb. 20, 2017, Supplementary European Search Report. [cited by applicant]
PCT/US2015/061242, Feb. 3, 2015, International Search Report and Written Opinion. [cited by applicant]
PCT/US2015/061242, May 6, 2016, International Preliminary Report on Patentability. [cited by applicant]
EP 14740444.6, Jun. 17, 2016, Extended European Search Report. [cited by applicant]
EP 18186356.4, Jan. 18, 2019, Extended European Search Report. [cited by applicant]
PCT/US2014/012107, Apr. 14, 2014, International Search Report and Written Opinion. [cited by applicant]
PCT/US2014/012107, Jun. 30, 2015, International Preliminary Report on Patentability. [cited by applicant]
EP 14856778.7, Feb. 28, 2017, Supplementary Partial European Search Report. [cited by applicant]
EP 14856778.7, Jun. 16, 2017, Supplementary European Search Report. [cited by applicant]
EP 20197583.6, Mar. 19, 2021, Extended European Search Report. [cited by applicant]
PCT/US2014/061247, Feb. 4, 2015, International Search Report and Written Opinion. [cited by applicant]
PCT/US2014/061247, May 6, 2016, International Preliminary Report on Patentability. [cited by applicant]
EP 20209278.9, May 4, 2021, Extended European Search Report. [cited by applicant]
PCT/US2016/057640, Jan. 26, 2017, International Search Report and Written Opinion. [cited by applicant]
PCT/US2016/057640, May 3, 2018, International Preliminary Report on Patentability. [cited by applicant]
Kaplan, Enzymatic pathways in the pathogenesis of hereditary angioedema: the role of C1 inhibitor therapy. J Allergy Clin Immunol. Nov. 2010;126(5):918-25. doi: 10.1016/j.jaci.2010.08.012. [cited by applicant]
Lunn et al., Ecallantide for the treatment of hereditary angioedema in adults. Clin Med Insights Cardiol. 2011;5:49-54. doi: 10.4137/CMC.S4434. Epub May 17, 2011. [cited by applicant]
EP 21158440.4, Oct. 25, 2021, Extended European Search Report. [cited by applicant]
EP 23164279.4, Sep. 21, 2023, Partial European Search Report. [cited by applicant]
EP 23164279.4, Jan. 2, 2024, Extended European Search Report. [cited by applicant]
EP 14856778.7, Jun. 29, 2021, Notice of Opposition to a European Patent. [cited by applicant]
EP 14856778.7, Jul. 5, 2021, Communication of Notices of Opposition. [cited by applicant]
EP 14856778.7, Feb. 8, 2022, Brief Communication. [cited by applicant]
EP 14856778.7, Mar. 25, 2022, Summons to attend oral proceedings. [cited by applicant]
EP 14856778.7, Feb. 7, 2023, Decision rejecting the opposition. [cited by applicant]
EP 14856778.7, Feb. 7, 2023, Minutes of the oral proceeding. [cited by applicant]
EP 20197583.6, Jun. 27, 2023, Communication pursuant to Article 94(3) EPC. [cited by applicant]
EP 23215946.7, May 6, 2024, Extended European Search Report. [cited by applicant]
[No Author Listed], “Incubate.” Merriam-Webster.com Dictionary, Merriam-Webster. Jul. 10, 2024. Accessed Aug. 9, 2024. https://www.merriam-webster.com/dictionary/incubate. [cited by applicant]
Adam et al., Human kininogens of low and high molecular mass: quantification by radioimmunoassay and determination of reference values. Clin Chem. Mar. 1985;31(3):423-6. [cited by applicant]
Alavi et al., Treatment of inflammatory bowel disease in a rodent model with the intestinal growth factor glucagon-like peptide-2. J Pediatr Surg. Jun. 2000;35(6):847-51. [cited by applicant]
Alving et al., Plasma prekallikrein: quantitative determination by direct activation with Hageman factor fragment (beta-XIIa). J Lab Clin Med. Feb. 1983;101(2):226-41. [cited by applicant]
Arican et al., Serum levels of TNF-alpha, IFN-gamma, IL-6, IL-8, IL-12, IL-17, and IL-18 in patients with active psoriasis and correlation with disease severity. Mediators Inflamm. Oct. 24, 2005;2005(5):273-9. doi: 10.1… [cited by applicant]
Babu et al., A Simple, Sensitive and Selective Fluorogenic Assay To Monitor Plasma Kallikrein Inhibitory Activity Of BCX4161 In Activated Plasma. J Allergy Clin Immunol. Feb. 2014;133(2). [cited by applicant]
Bantia et al., BCX-4161, a Small Molecule and Orally Biovailable Plasma Kallikrein Inhibitor for the Treatment of Hereditary Angioedema. J Allergy Clin Immunol. Feb. 2013;131(2). [cited by applicant]
Bedi et al., Monoclonal antibodies to bradykinin inhibit smooth muscle contractile action of bradykinin. Biochim Biophys Acta. Sep. 27, 1985;842(1):90-9. doi: 10.1016/0304-4165(85)90298-3. [cited by applicant]
Bhattacharjee et al., Inhibition of vascular permeability by antisense-mediated inhibition of plasma kallikrein and coagulation factor 12. Nucleic Acid Ther. Jun. 2013;23(3):175-87. doi: 10.1089/nat.2013.0417. Epub Apr.… [cited by applicant]
Busse et al., Specific Targeting of Plasma Kallikrein for Treatment of Hereditary Angioedema: A Revolutionary Decade. J Allergy Clin Immunol Pract. Mar. 2022; 10(3):716-722. doi: 10.1016/j.jaip.2021.11.011. Epub Nov. 25… [cited by applicant]
Cool et al., Characterization of human blood coagulation factor XII cDNA. J Biol Chem. Nov. 5, 1985;260(25):13666-76. [cited by applicant]
Dai et al., Role of plasma kallikrein-kinin system activation in synovial recruitment of endothelial progenitor cells in experimental arthritis. Arthritis Rheum. Nov. 2012;64(11):3574-82. doi: 10.1002/art.34607. [cited by applicant]
Eidelman, Hereditary angioedema: New therapeutic options for a potentially deadly disorder. BMC Blood Disord. May 14, 2010;10:3. doi: 10.1186/1471-2326-10-3. [cited by applicant]
Favilli et al., IL-18 activity in systemic lupus erythematosus. Ann N Y Acad Sci. Sep. 2009;1173:301-9. doi: 10.1111/j.1749-6632.2009.04742.x. [cited by applicant]
Folsom et al., Plasma Concentrations of High Molecular Weight Kininogen and Prekallikrein and Venous Thromboembolism Incidence in the General Population. Thromb Haemost. May 2019;119(5):834-843. doi: 10.1055/s-0039-1678… [cited by applicant]
Gallimore et al., Simple chromogenic peptide substrate assays for determining prekallikrein, kallikrein inhibition and kallikrein “like” activity in human plasma. Thromb Res. Feb. 1, 1982;25(3):293-8. [cited by applicant]
Golas et al., A comparison of blood factor XII autoactivation in buffer, protein cocktail, serum, and plasma solutions. Biomaterials. Jan. 2013;34(3):607-20. doi: 10.1016/j.biomaterials.2012.09.034. Epub Oct. 30, 2012. [cited by applicant]
Gracie et al., A proinflammatory role for IL-18 in rheumatoid arthritis. J Clin Invest. Nov. 1999;104(10):1393-401. doi: 10.1172/JCI7317. [cited by applicant]
Harpel et al., Distribution of plasma kallikrein between C-1 inactivator and alpha 2-macroglobulin in plasma utilizing a new assay for alpha 2-macroglobulin-kallikrein complexes. J Biol Chem. Apr. 10, 1985;260(7):4257-6… [cited by applicant]
Hewlett et al., ‘I'm hurting, I want to kill myself’: rheumatoid arthritis flare is more than a high joint count—an international patient perspective on flare where medical help is sought. Rheumatology (Oxford). Jan. 20… [cited by applicant]
Jaffa et al., Longitudinal Plasma Kallikrein Levels and Their Association With the Risk of Cardiovascular Disease Outcomes in Type 1 Diabetes in DCCT/EDIC. Diabetes. Nov. 2020;69(11):2440-2445. doi: 10.2337/db20-0427. E… [cited by applicant]
Joseph et al., Factor XII-independent activation of the bradykinin-forming cascade: Implications for the pathogenesis of hereditary angioedema types I and II. J Allergy Clin Immunol. Aug. 2013;132(2):470-5. doi: 10.1016… [cited by applicant]
Kahn et al., Kinin system activation in vasculitis. Acta Paediatr. Jul. 2011;100(7):950-7. doi: 10.1111/j.1651-2227.2011.02266.x. Epub Apr. 8, 2011. [cited by applicant]
Kaufman et al., Alpha 2-macroglobulin-kallikrein complexes detect contact system activation in hereditary angioedema and human sepsis. Blood. Jun. 15, 1991;77(12):2660-7. [cited by applicant]
Lehmann A., Ecallantide (DX-88), a plasma kallikrein inhibitor for the treatment of hereditary angioedema and the prevention of blood loss in on-pump cardiothoracic surgery. Expert Opin Biol Ther. Aug. 2008;8(8):1187-99… [cited by applicant]
Lewin et al., Studies of C1 inactivator-plasma kallikrein complexes in purified systems and in plasma. J Biol Chem. May 25, 1983;258(10):6415-21. [cited by applicant]
Lochner et al., Anti-interleukin-18 therapy in murine models of inflammatory bowel disease. Pathobiology. 2002;70(3):164-9. doi: 10.1159/000068149. [cited by applicant]
Losy et al., IL-18 in patients with multiple sclerosis. Acta Neurol Scand. Sep. 2001;104(3):171-3. doi: 10.1034/j.1600-0404.2001.00356.x. [cited by applicant]
Monteleone et al., Bioactive IL-18 expression is up-regulated in Crohn's disease. J Immunol. Jul. 1, 1999;163(1):143-7. [cited by applicant]
Parikh et al., Prospective study of plasma high molecular weight kininogen and prekallikrein and incidence of coronary heart disease, ischemic stroke and heart failure. Thromb Res. Oct. 2019;182:89-94. doi: 10.1016/j.th… [cited by applicant]
Porsteinsson et al., Diagnosis of Early Alzheimer's Disease: Clinical Practice in 2021. J Prev Alzheimers Dis. 2021;8(3):371-386. doi: 10.14283/jpad.2021.23. [cited by applicant]
Potter et al., Strict Preanalytical Oral Glucose Tolerance Test Blood Sample Handling Is Essential for Diagnosing Gestational Diabetes Mellitus. Diabetes Care. Jul. 2020;43(7):1438-1441. doi: 10.2337/dc20-0304. Epub Apr… [cited by applicant]
Saito et al., Human plasma prekallikrein (Fletcher factor) clotting activity and antigen in health and disease. J Lab Clin Med. Jul. 1978;92(1):84-95. [cited by applicant]
Sano M., Changes of High Molecular Weight Kininogen in Various States. Clinical Blood. Oct. 1989;30(10):1708-1712. [cited by applicant]
Saxena et al., Lupus nephritis: current update. Arthritis Res Ther. 2011;13(5):240. doi: 10.1186/ar3378. Epub Sep. 28, 2011. [cited by applicant]
Sexton et al., Declaration by Dr. Daniel Sexton and Dr. John Kenniston. Nov. 2021. 15 pages. [cited by applicant]
Siles R., Hereditary Angioedema. Cleveland Clinic, Disease Management. Apr. 2017. Last Reviewed: Dec. 2017. 8 pages. [cited by applicant]
Singh et al., Increased plasma bradykinin level is associated with cognitive impairment in Alzheimer's patients. Neurobiol Dis. Jun. 2020;139:104833. doi: 10.1016/j.nbd.2020.104833. Epub Mar. 12, 2020. Author Manuscript… [cited by applicant]
Stadnicki et al., Activation of plasma contact and coagulation systems and neutrophils in the active phase of ulcerative colitis. Dig Dis Sci. Nov. 1997;42(11):2356-66. doi: 10.1023/a:1018891323205. [cited by applicant]
Strongin W., Sensitivity, specificity, and predictive value of diagnostic tests: definitions and clinical applications. In: Laboratory diagnosis of viral infections. 1992. Lennette E.H., Ed. Chapter 10:211-9. [cited by applicant]
Tang et al., Release of bradykinin and substance P by Heating hind paw of Rat. Acta Pharmacologica Sinica. May 1, 1994;15(3):232-4. [cited by applicant]
Tankersley et al., Kinetics of activation and autoactivation of human factor XII. Biochemistry. Jan. 17, 1984;23(2):273-9. doi: 10.1021/bi00297a016. [cited by applicant]
Villeda-Ramírez et al., Interleukin-18 upregulation is associated with the use of steroids in patients with ulcerative colitis. Inflamm Bowel Dis. Jun. 2011;17(6):E50-1. doi: 10.1002/ibd.21700. Epub Mar. 31, 2011. [cited by applicant]
Xie et al., Discovery and development of plasma kallikrein inhibitors for multiple diseases. Eur J Med Chem. Mar. 15, 2020;190:112137. doi: 10.1016/j.ejmech.2020.112137. Epub Feb. 10, 2020. [cited by applicant]
Yu et al., Validation of kininogen 1 as a serum molecular marker of proliferative vitreoretinopathy. Recent Advances in Ophthalmology. Aug. 5, 2009;29(8):561-4. [cited by applicant]
Zamolodchikov et al., Activation of the factor XII-driven contact system in Alzheimer's disease patient and mouse model plasma. Proc Natl Acad Sci U S A. Mar. 31, 2015;112(13):4068-73. doi: 10.1073/pnas.1423764112. Epub… [cited by applicant]
Zhang et al., A Simple, Sensitive and Selective Fluorogenic Assay to Monitor Kallikrein Activity in Activated Plasma. J Allergy Clin Immunol. Feb. 2013;131(2). [cited by applicant]
Bernstein et al., Emerging concepts in the diagnosis and treatment of patients with undifferentiated angioedema. Int J Emerg Med. Nov. 6, 2012;5(1):39. doi: 10.1186/1865-1380-5-39. [cited by applicant]